Squarepoint Portfolio holdings
Squarepoint runs funds that use computer models to trade many kinds of assets around the world. It began as nQuant, a trading unit set up inside Lehman Brothers in 2000 by its founders, Olivier Durantel and Gregoire Schneider. Barclays took over nQuant in 2008, and in December 2014 it was spun off as an independent firm and renamed Squarepoint. In 2022 Squarepoint formed STG, a separate trading group that shares much of its infrastructure but has its own investment staff, and in 2021 it partnered with Arini Capital, a European hedge fund.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Costco
COST
|
+$305M |
| 2 |
Procter & Gamble
PG
|
+$300M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$274M |
| 4 |
NVIDIA
NVDA
|
+$268M |
| 5 |
Lowe's Companies
LOW
|
+$253M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$1.23B |
| 2 |
State Street Communication Services Select Sector SPDR ETF
XLC
|
+$536M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$470M |
| 4 |
ExxonMobil
XOM
|
+$370M |
| 5 |
Amazon
AMZN
|
+$245M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.61% |
| 2 | Technology | 13.44% |
| 3 | Consumer Discretionary | 5.63% |
| 4 | Financials | 5.29% |
| 5 | Healthcare | 5.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2801
Iovance Biotherapeutics
IOVA
$3.53B
| $941K | ﹤0.01% |
63,462
-262,120
| -81% | -$1.88M |
2024 Q2
9 quarters
|
|
2802
Lexicon Pharmaceuticals
LXRX
$810M
| $940K | ﹤0.01% |
501,186
+489,445
| +4,169% | +$1.09M |
2026 Q2
1 quarter
|
|
2803
Santacruz Silver Mining Ltd
SCZM
$656M
| $940K | ﹤0.01% |
106,409
+69,757
| +190% | +$572K |
2026 Q2
1 quarter
|
|
2804
BancFirst
BANF
$3.99B
| $939K | ﹤0.01% |
8,922
+1,738
| +24% | +$196K |
2026 Q1
2 quarters
|
|
2805
Hillman Solutions
HLMN
$1.53B
| $937K | ﹤0.01% |
134,099
+100,427
| +298% | +$796K |
2025 Q2
5 quarters
|
|
2806
Cadre Holdings
CDRE
$1.42B
| $937K | ﹤0.01% |
37,332
+9,909
| +36% | +$297K |
2026 Q2
1 quarter
|
|
2807
PUT
F5
FFIV
$18B
| $935K | ﹤0.01% |
2,100
-1,100
| -34% | -$452K |
2026 Q1
2 quarters
|
|
2808
Barnes & Noble Education
BNED
$440M
| $935K | ﹤0.01% |
80,659
+18,151
| +29% | +$218K |
2026 Q2
1 quarter
|
|
2809
Wipro
WIT
$21.1B
| $935K | ﹤0.01% |
566,441
+195,246
| +53% | +$358K |
2024 Q1
10 quarters
|
|
2810
CALL
Enbridge
ENB
$107B
| $934K | ﹤0.01% |
20,100
-12,500
| -38% | -$646K |
2024 Q4
7 quarters
|
|
2811
Atrium Therapeutics
RNA
$128M
| $932K | ﹤0.01% |
112,535
-34,208
| -23% | -$404K |
2026 Q1
2 quarters
|
|
2812
Terrestrial Energy
IMSR
$265M
| $931K | ﹤0.01% |
239,434
+153,934
| +180% | +$800K |
2025 Q4
3 quarters
|
|
2813
NOV
NOV
$6.35B
| $931K | ﹤0.01% |
49,691
-191,482
| -79% | -$3.85M |
2022 Q2
17 quarters
|
|
2814
CALL
e.l.f. Beauty
ELF
$6.72B
| $929K | ﹤0.01% |
9,200
-44,200
| -83% | -$4.04M |
2024 Q2
9 quarters
|
|
2815
KeyCorp
KEY
$22.5B
| $927K | ﹤0.01% |
46,192
+857
| +2% | +$19K |
2018 Q3
32 quarters
|
|
2816
Teekay
TK
$1.17B
| $924K | ﹤0.01% |
+64,815
| New | +$802K |
2026 Q3
0 quarters
|
|
2817
CALL
Five Below
FIVE
$13.6B
| $922K | ﹤0.01% |
4,200
-18,500
| -81% | -$4.15M |
2026 Q1
2 quarters
|
|
2818
Compass Pathways
CMPS
$1.29B
| $922K | ﹤0.01% |
74,128
-64,543
| -47% | -$858K |
2025 Q4
3 quarters
|
|
2819
Abacus Global Management
ABX
$858M
| $921K | ﹤0.01% |
114,272
+58,721
| +106% | +$576K |
2024 Q4
7 quarters
|
|
2820
CALL
Eldorado Gold
EGO
$8.31B
| $916K | ﹤0.01% |
23,800
-16,700
| -41% | -$633K |
2026 Q2
1 quarter
|
|
2821
Electrovaya
ELVA
$237M
| $916K | ﹤0.01% |
140,468
+126,606
| +913% | +$983K |
2026 Q2
1 quarter
|
|
2822
CALL
Molson Coors Class B
TAP
$7.33B
| $915K | ﹤0.01% |
+25,100
| New | +$1.01M |
2026 Q3
0 quarters
|
|
2823
Amphastar Pharmaceuticals
AMPH
$1.23B
| $915K | ﹤0.01% |
35,435
-43,360
| -55% | -$937K |
2022 Q4
15 quarters
|
|
2824
Unity Bancorp
UNTY
$588M
| $914K | ﹤0.01% |
16,858
-5,383
| -24% | -$314K |
2025 Q2
5 quarters
|
|
2825
PUT
KKR & Co
KKR
$86.7B
| $913K | ﹤0.01% |
10,000
-105,000
| -91% | -$10.7M |
2021 Q2
21 quarters
|
|
Similar funds
Squarepoint's Q3 2026 Portfolio in Review
As of Q3 2026, Squarepoint held 5,201 positions worth $90.8B, up 0.33% from $90.5B the previous quarter. Its ten largest holdings account for 22% of the portfolio.
Squarepoint withdrew a net $4.18B in Q3 2026, closing 849 positions and reducing 1,820 holdings. Its most notable exit was Electronic Arts, an estimated $146M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 56% of assets, up from 53% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Squarepoint opened a new position in AstraZeneca worth $188M.
- Squarepoint's largest Q3 2026 buy was AstraZeneca: 1,161,691 shares worth $188M.
- Squarepoint added most to Costco in Q3 2026, an estimated $305M increase.
- Squarepoint's biggest Q3 2026 reduction was iShares Core S&P 500 ETF, cutting an estimated $1.23B.
- Squarepoint fully exited Electronic Arts in Q3 2026, selling an estimated $146M.
- Squarepoint's ten largest holdings make up 22% of its $90.8B portfolio in Q3 2026.
- Squarepoint opened 873 new positions and closed 849 in Q3 2026.
- Squarepoint's portfolio value rose 0.33% quarter-over-quarter to $90.8B.
Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.